Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics
Kelsey J Weigel1, Luqun Shen1, Clayton L Thomas1
1Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
Abstract:
Immunotoxins are chimeric proteins comprising a specific cellular targeting domain linked to a cytotoxic factor. Here we describe the design and use of a novel, peptide-based immunotoxin that can initiate selective cytotoxicity on ErbB2-positive cells. ErbB2 is a receptor tyrosine kinase that is overexpressed in the tumor cells of approximately 30% of breast cancer patients. Immunotoxin candidates were designed to incorporate a targeting ligand with affinity for ErbB2 along with a membrane lysin-based toxin domain. One particular peptide candidate, NL1.1-PSA, demonstrated selective cytotoxicity towards ErbB2-overexpressing cell lines. We utilized a bioengineering strategy to show that recombinant NL1.1-PSA immunotoxin expression by Escherichia coli also conferred selective cytotoxicity towards ErbB2-overexpressing cells. Our findings hold significant promise for the use of effective immunotoxins in cancer therapeutics.
Insights
Researchers developed a novel peptide immunotoxin targeting ErbB2-positive cancer cells. This engineered immunotoxin, NL1.1-PSA, selectively kills tumor cells, showing promise for new cancer therapies.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Immunotoxins are engineered proteins for targeted cancer therapy.
- ErbB2 receptor tyrosine kinase is overexpressed in ~30% of breast cancers.
- Targeting ErbB2 offers a potential strategy for selective cancer treatment.
Purpose of the Study:
- To design and evaluate a novel peptide-based immunotoxin targeting ErbB2-positive cells.
- To assess the selective cytotoxicity of the engineered immunotoxin.
- To explore the therapeutic potential of this new immunotoxin in cancer.
Main Methods:
- Design of immunotoxin candidates incorporating an ErbB2-targeting ligand and a membrane lysin-based toxin.
- Evaluation of selective cytotoxicity in ErbB2-overexpressing cell lines.
- Bioengineering strategy for recombinant NL1.1-PSA immunotoxin expression in Escherichia coli.
Main Results:
- The peptide candidate NL1.1-PSA demonstrated selective cytotoxicity against ErbB2-overexpressing cell lines.
- Recombinant NL1.1-PSA immunotoxin expressed in E. coli also showed selective cytotoxicity.
- The engineered immunotoxin effectively targeted and killed ErbB2-positive cancer cells.
Conclusions:
- The novel peptide-based immunotoxin NL1.1-PSA exhibits selective cytotoxicity towards ErbB2-positive cells.
- Engineering immunotoxins for targeted cancer therapy is a viable approach.
- This research holds significant promise for developing effective immunotoxin-based cancer therapeutics.
